|
1
|
Albini A, Pennesi G, Donatelli F,
Cammarota R, De Flora S and Noonan DM: Cardiotoxicity of anticancer
drugs: The need for cardio-oncology and cardio-oncological
prevention. J Natl Cancer Inst. 102:14–25. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
SEER Cancer Stat Facts: Female Breast
Cancer. National Cancer Institute; Bethesda, MD: 2016, http://seer.cancer.gov/statfacts/html/breast.htmlApril.
2019
|
|
3
|
Canadian Cancer Society's Advisory
Committee on Cancer Statistics: Canadian cancer statistics 2016.
Canadian Cancer Society. (Toronto, ON). 2016.
|
|
4
|
Cai FF, Kohler C, Zhang B, Wang MH, Chen
WJ and Zhong XY: Epigenetic therapy for breast cancer. Int J Mol
Sci. 12:4465–4487. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alvarez RH: Present and future evolution
of advanced breast cancer therapy. Breast Cancer Res. 12 (Suppl
2):S12010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu
YL, Liu LF and Yeh ET: Identification of the molecular basis of
doxorubicin-induced cardiotoxicity. Nat Med. 18:1639–1642. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mitry MA and Edwards JG: Doxorubicin
induced heart failure: Phenotype and molecular mechanisms. Int J
Cardiol Heart Vasc. 10:17–24. 2016.PubMed/NCBI
|
|
9
|
Tocchetti CG, Cadeddu C, Di Lisi D,
Femminò S, Madonna R, Mele D, Monte I, Novo G, Penna C, Pepe A, et
al: From molecular mechanisms to clinical management of
antineoplastic drug-induced cardiovascular toxicity: A
translational overview. Antioxid Redox Signal. May 15–2017.(Epub
ahead of print). PubMed/NCBI
|
|
10
|
Kaiserová H, Simůnek T, van der Vijgh WJ,
Bast A and Kvasnicková E: Flavonoids as protectors against
doxorubicin cardiotoxicity: Role of iron chelation, antioxidant
activity and inhibition of carbonyl reductase. Biochim Biophys
Acta. 1772:1065–1074. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stewart DJ, Grewaal D, Green RM, Mikhael
N, Goel R, Montpetit VA and Redmond MD: Concentrations of
doxorubicin and its metabolites in human autopsy heart and other
tissues. Anticancer Res. 13:1945–1952. 1993.PubMed/NCBI
|
|
12
|
Mordente A, Meucci E, Silvestrini A,
Martorana GE and Giardina B: New developments in
anthracycline-induced cardiotoxicity. Curr Med Chem. 16:1656–1672.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sanguinetti MC and Tristani-Firouzi M:
hERG potassium channels and cardiac arrhythmia. Nature.
440:463–469. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vandenberg JI, Perry MD, Perrin MJ, Mann
SA, Ke Y and Hill AP: hERG K(+) channels: Structure, function, and
clinical significance. Physiol Rev. 92:1393–1478. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jehle J, Schweizer PA, Katus HA and Thomas
D: Novel roles for hERG K(+) channels in cell proliferation and
apoptosis. Cell Death Dis. 2:e1932011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Curran ME, Splawski I, Timothy KW, Vincent
GM, Green ED and Keating MT: A molecular basis for cardiac
arrhythmia: HERG mutations cause long QT syndrome. Cell.
80:795–803. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jaworski C, Mariani JA, Wheeler G and Kaye
DM: Cardiac complications of thoracic irradiation. J Am Coll
Cardiol. 61:2319–2328. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jain D, Russell RR, Schwartz RG, Panjrath
GS and Aronow W: Cardiac complications of cancer therapy:
Pathophysiology, identification, prevention, treatment, and future
directions. Curr Cardiol Rep. 19:362017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang G and Liu S: Research progress in
cardiotoxicity of antitumor chemotherapy drugs. J Oncol.
21:1010–1014. 2015.
|
|
20
|
Manrique CR, Park M, Tiwari N, Plana JC
and Garcia MJ: Diagnostic strategies for early recognition of
cancer therapeutics-related cardiac dysfunction. Clin Med Insights
Cardiol. 11:11795468176979832017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Von Hoff DD, Layard MW, Basa P, Davis HL
Jr, Von Hoff AL, Rozencweig M and Muggia FM: Risk factors for
doxorubicin-induced congestive heart failure. Ann Intern Med.
91:710–717. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ryberg M, Nielsen D, Cortese G, Nielsen G
and Andersen PK: New insight into epirubicin cardiac toxicity:
Competing risks analysis of 1097 breast cancer patients. J Natl
Cancer Inst. 100:1058–1067. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Swain SM, Whaley FS and Ewer MS:
Congestive heart failure in patients treated with doxorubicin: A
retrospective analysis of three trials. Cancer. 97:2869–2879. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tromp J, Steggink LC, Van Veldhuisen DJ,
Gietema JA and van der Meer P: Cardio-oncology: Progress in
diagnosis and treatment of cardiac dysfunction. Clin Pharmacol
Ther. 101:481–490. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hortobagyi GN, Frye D, Buzdar AU, Ewer MS,
Fraschini G, Hug V, Ames F, Montague E, Carrasco CH, Mackay B, et
al: Decreased cardiac toxicity of doxorubicin administered by
continuous intravenous infusion in combination chemotherapy for
metastatic breast carcinoma. Cancer. 63:37–45. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
EBCTCG (Early Breast Cancer Trialists'
Collaborative Group), . Effect of radiotherapy after mastectomy and
axillary surgery on 10-year recurrence and 20-year breast cancer
mortality: Meta-analysis of individual patient data for 8135 women
in 22 randomised trials. Lancet. 383:2127–2135. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pein F, Sakiroglu O, Dahan M, Lebidois J,
Merlet P, Shamsaldin A, Villain E, de Vathaire F, Sidi D and
Hartmann O: Cardiac abnormalities 15 years and more after
Adriamycin therapy in 229 childhood survivors of a solid tumors at
the Institute Gustave Roussy. Brit J Cancer. 91:37–44. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schmitz KH, Prosnitz RG, Schwartz AL and
Carver JR: Prospective surveillance and management of cardiac
toxicity and health in breast cancer survivors. Cancer. 118 (Suppl
8):S2270–S2276. 2012. View Article : Google Scholar
|
|
29
|
Lang RM, Badano LP, Mor-Avi V, Afilalo J,
Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA,
Kuznetsova T, et al: Recommendations for cardiac chamber
quantification by echocardiography in adults: An update from the
American society of echocardiography and the European association
of cardiovascular imaging. J Am Soc Echocardiogr. 28:1–39.e14.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tassan-Mangina S, Codorean D, Metivier M,
Costa B, Himberlin C, Jouannaud C, Blaise AM, Elaerts J and
Nazeyrollas P: Tissue Doppler imaging and conventional
echocardiography after anthracycline treatment in adults: Early and
late alterations of left ventricular function during a prospective
study. Eur J Echocardiogr. 7:141–146. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jurcut R, Wildiers H, Ganame J, D'hooge J,
De Backer J, Denys H, Paridaens R, Rademakers F and Voigt JU:
Strain rate imaging detects early cardiac effects of pegylated
liposomal doxorubicin as adjuvant therapy in elderly patients with
breast cancer. J Am Soc Echocardiogr. 21:1283–1289. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mitani I, Jain D, Joska TM, Burtness B and
Zaret BL: Doxorubicin cardiotoxicity: Prevention of congestive
heart failure with serial cardiac function monitoring with
equilibrium radionuclide angio-cardiography in the current era. J
Nucl Cardiol. 10:132–139. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
van Royen N, Jaffe CC, Krumholz HM,
Johnson KM, Lynch PJ, Natale D, Atkinson P, Deman P and Wackers FJ:
Comparison and reproducibility of visual echocardiographic and
quantitative radionuclide left ventricular ejection fractions. Am J
Cardiol. 77:843–850. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Armstrong AC, Gidding S, Gjesdal O, Wu C,
Bluemke DA and Lima JA: LV mass assessed by echocardiography and
CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc
Imaging. 5:837–848. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ng R, Better N and Green MD: Anticancer
agents and cardiotoxicity. Semin Oncol. 33:2–14. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McGowan JV, Chung R, Maulik A, Piotrowska
I, Walker JM and Yellon DM: Anthracycline chemotherapy and
cardiotoxicity. Cardiovasc Drugs Ther. 31:63–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Herman EH, Zhang J, Lipshultz SE, Rifai N,
Chadwick D, Takeda K, Yu ZX and Ferrans VJ: Correlation between
serum levels of cardiac troponin-T and the severity of the chronic
cardiomyopathy induced by doxorubicin. J Clin Oncol. 17:2237–2243.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lipshultz SE, Rifai N, Sallan SE, Lipsitz
SR, Dalton V, Sacks DB and Ottlinger ME: Predictive value of
cardiac troponin T in pedriatic patirnts at risk for myocardial
injury. Circulation. 96:2641–2648. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Porcel JM: Utilization of B-type
natriuretic peptide and NT-proBNP in the diagnosis of pleural
effusions due to heart failure. Curr Opin Pulm Med. 17:215–219.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang N, Zheng L, Zheng J, et al:
Significance of N-terminal pro-brain natriuretic peptide in early
monitoring of anthracycline chemotherapy in elderly patients with
breast cancer. Chin J Gerontol. 6:2931–2933. 2014.
|
|
41
|
Angelis AD, Cappetta D, Berrino L and
Urbanek K: Doxorubicin cardiotoxicity: Multiple targets and
translational perspectives. IntechOpen. https://www.intechopen.com/books/cardiotoxicity/doxorubicin-cardiotoxicity-multiple-targets-and-translational-perspectivesNovember
14–2008
|
|
42
|
De Angelis A, Urbanek K, Cappetta D,
Piegari E, Pia Ciuffreda L, Rivellino A, Russo R, Esposito G, Rossi
F and Berrino L: Doxorubicin cardiotoxicity and target cells: A
broader perspective. Cardiooncology. 2:22016.
|
|
43
|
van Dalen EC, van der Pal HJ, Caron HN and
Kremer LC: Different dosage schedules for reducing cardiotoxicity
in cancer patients receiving anthracycline chemotherapy. Cochrane
Database Syst Rev. CD0050082009.PubMed/NCBI
|
|
44
|
Torti FM, Bristow MR, Howes AE, Aston D,
Stockdale FE, Carter SK, Kohler M, Brown BW Jr and Billingham ME:
Reduced cardiotoxicity of doxorubicin delivered on a weekly
schedule: Assessment by endomyocardial biopsy. Ann Intern Med.
99:745–749. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Koene RJ, Prizment AE, Blaes A and Konety
SH: Shared risk factors in cardiovascular disease and cancer.
Circulation. 133:1104–1114. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Harris L, Batist G, Belt R, Rovira D,
Navari R, Azarnia N, Welles L and Winer E; TLC D-99 Study Group, :
Liposome-encapsulated doxorubicin compared with conventional
doxorubicin in a randomized multicenter trial as first-line therapy
of metastastic breast carcinoma. Cancer. 94:25–36. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Minotti G, Menna P, Salvatorelli E, Cairo
G and Gianni L: Anthracyclines: Molecular advances and
pharmacologic developments in antitumor activity and
cardiotoxicity. Pharmacol Rev. 56:185–229. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Van Dalen EC, Caron HN, Dickinson HO and
Kremer LC: Cardioprotective interventions for cancer patients
receiving anthracyclines. Cochrane Database Syst Rev.
CD0039172008.PubMed/NCBI
|
|
49
|
Che FF, Liu Y and Xu CG: Study on the
effect and mechanism of dextromethionine on cardiotoxicity induced
by doxorubicin. J Sichuan Univ. 41:24–28. 2010.
|
|
50
|
Gao X, Han Z and Du X: Observation of the
effects of dextromethine on cardiotoxicity induced by epirubicin.
Chin J Cancer Prev Treat. 17:296–298. 2010.
|
|
51
|
Professional Committee of Breast Cancer of
China Anti-Cancer Association, . Basic principles of chemotherapy
for recurrent and metastatic breast cancer. Chin J Med. 9:73–75.
2011.
|
|
52
|
Sacco G, Bigioni M, Evangelista S, Goso C,
Manzini S and Maggi CA: Cardioprotection effects of zofenopril, a
new angiotension-converting enzyme inhibitor, on
doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol.
414:71–78. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sacco G, Mario B, Lopez G, Evangelista S,
Manzini S and Maggi CA: ACE inhibition and protection from
doxorubicin-induced cardiotoxicity in the rat. Vascul Pharmacol.
50:166–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kalay N, Basar E, Ozdogru I, Er O,
Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R and
Ergin A: Protective effects of carvedilol against
anthracycline-induced cardiomyopathy. J Am Coll Cardiol.
48:2258–2262. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Elbaky NAA, El-Orabi NF, Fadda LM,
Abd-Elkader OH and Ali HM: Role of N-acetylcysteine and coenzyme
Q10 in the amelioration of myocardial energy expenditure and
oxidative stress, induced by carbon tetrachloride intoxication in
rats. Dose-Response. 16:15593258187901582018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Baker WL, Anglade MW, Baker EL, White CM,
Kluger J and Coleman CI: Use of N-acetylcysteine to reduce
post-cardiothoracic surgery complications: A meta-analysis. Eur J
Cardiothorac Surg. 35:521–527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kumar A, Kaur H, Devi P and Mohan V: Role
of coenzyme Q10 (CoQ10) in cardiac disease, hypertension, and
meniere-like syndrome. Pharmacol Ther. 124:259–268. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
van Acker FA, Boven E, Kramer K, Haenen
GR, Bast A and van der Vijgh WJ: Frederine, a new and promising
protector against doxorubicin-induced cardiotoxicity. Clin Cancer
Res. 7:1378–1384. 2001.PubMed/NCBI
|
|
59
|
Mehta LS, Watson KE, Barac A, Beckie TM,
Bittner V, Cruz-Flores S, Dent S, Kondapalli L, Ky B, Okwuosa T, et
al: Cardiovascular disease and breast cancer: Where these entities
intersect: A scientific statement from the American heart
association. Circulation. 137:e30–e66. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Khouri MG, Douglas PS, Mackey JR, Martin
M, Scott JM, Scherrer-Crosbie M and Jones LW: Cancer
therapy-induced cardiac toxicity in early breast cancer: Addressing
the unresolved issues. Circulation. 126:2749–2763. 2012. View Article : Google Scholar : PubMed/NCBI
|
